Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial
Eli Lilly reported that a new combination drug regimen, pairing eloralintide with tirzepatide, resulted in significantly higher weight loss than tirzepatide alone in a mid-stage trial. The company plans to advance the treatment to Phase 3 trials later this year.
Why it matters
This development represents a potential breakthrough in obesity and diabetes treatment, offering a more effective alternative for patients who do not respond sufficiently to current GLP-1 medications.
Eli Lilly on Wednesday said its experimental combination regimen resulted in greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 diabetes.
The combo therapy met the study's main goals in a population that typically struggles to lose weight. The results raise hopes that the combo regimen could serve as an alternative blockbuster treatment option for people who didn't see the results they wanted from using the current GLP-1 products on the market. Lilly said it plans to start Phase 3 trials on the regimen at the end of the year.
The combination treatment combines Lilly's experimental drug eloralintide, which targets amylin — a hormone in the pancreas involved in appetite and satiety — with a low dose of tirzepatide, the active ingredient in its obesity injection Zepbound and its diabetes counterpart Mounjaro.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in